Defirox

/ Dexcel

Transfusional iron overload: The recommended initial daily dose of the product is 20 mg/kg body weight.
Non-transfusion-dependent thalassemia syndromes: The recommended initial daily dose of the product in patients with non-transfusion-dependent thalassaemia syndromes is 10 mg/kg body weight.
Please refer to the license holder for further details.

For the treatment of chronic iron overload caused by blood transfusions (transfusional haemosiderosis) in adult and paediatric patients (aged 2 years and over).
For the treatment of chronic iron overload in patients with non-transfusion-dependent thalassaemia syndromes aged 10 years and older.
Chelation therapy should only be initiated when there is evidence of iron overload (liver iron concentration [LIC] ≥5 mg Fe/g dry weight [dw] or serum ferritin consistently >800 μg/l). LIC is the preferred method of iron overload determination and should be used wherever available.

Hypersensitivity to the active substance or to any of the excipients.
Combination with other iron chelator therapies as the safety of such combinations has not been established.
Patients with estimated creatinine clearance <60 ml/min.

Please refer to the license holder for further details.

Please refer to the license holder for further details.

Please refer to the license holder for further details.

Please refer to the license holder for further details.

Please refer to the license holder for further details.